EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The compatibility of oxytocin and tranexamic acid injection products when mixed for co‐administration by infusion for the treatment of postpartum haemorrhage: An in vitro investigation

Pete Lambert, Alessandra Tomazzini, Philip Wright, Claire McEvoy, Ioannis D Gallos, Anne Ammerdorffer iD, Lester Chinery, Arri Coomarasamy, Ahmet Metin Gülmezoglu iD

BJOG: An International Journal of Obstetrics & Gynaecology · 2023

DOI: 10.1111/1471-0528.17398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2023. Verfasst von Pete Lambert und 8 weiteren Autor:innen. Beteiligte Einrichtung: Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Postpartum Hemorrhage, Tranexamic Acid, Antifibrinolytic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Gates Foundation, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the compatibility of oxytocin and tranexamic acid injection products when mixed for the purpose of co‐administration by intravenous infusion.

Design

Compatibility testing.

Setting

Hospitals taking part in a multicentre postpartum haemorrhage treatment (E‐MOTIVE) trial in Kenya, Nigeria, Tanzania and South Africa. Sample Oxytocin and tranexamic acid products.

Methods

The compatibility of two sentinel products of oxytocin injection and tranexamic acid injection in 200‐mL infusion bags of both 0.9% w/v saline and Ringer's lactate solution was assessed. We analysed all tranexamic acid–oxytocin combinations, and each evaluation was conducted for up to 3 h. Subsequently, the compatibility of multiple tranexamic acid products with reference oxytocin products when mixed in 0.9% w/v saline over a period of 1 h was investigated. Main outcome measures Concentration of oxytocin over time after mixing with tranexamic acid products.

Results

We found significant interaction between certain oxytocin and tranexamic acid products after mixing them in vitro and observing for 1 h. The interaction substantially impacted oxytocin content leading to reduction in concentration (14.8%–29.0%) immediately on mixing ( t = 0 min). In some combinations, the concentration continued to decline throughout the stability assessment period. Oxytocin loss was observed in 7 out of 22 (32%) of combinations tested.

Conclusions

In a clinical setting, mixing certain oxytocin and tranexamic acid products before administration may result in an underdosing of oxytocin, compromising care in an emergency life‐threatening situation. The mixing of oxytocin and tranexamic acid injection products for co‐administration with intravenous infusion fluids should be avoided until the exact nature of the observed interaction and its implications are understood.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Postpartum HemorrhageTranexamic AcidAntifibrinolytic AgentsFemaleHumansOxytocinInfusions, Intravenous

Stichwörter der Autor:innen

co-administrationdrug interactionintravenous infusionoxytocinpostpartum haemorrhagetranexamic acid

Substanzen

OxytocinTranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Concept Foundation, Geneva, Switzerland.
  • Concept Foundation, Bangkok, Thailand.
  • Institute of Metabolism and Systems Research (IMSR), WHO Collaborating Centre for Global Women's Health Research, University of Birmingham, Birmingham, UK.

ORCID-Profile: Anne Ammerdorffer, Ahmet Metin Gülmezoglu

Förderung

  • Medical Research Council
  • Gates Foundation
  • Bill and Melinda Gates Foundation

Zitieren

APA

Lambert, P., Tomazzini, A., Wright, P., McEvoy, C., Gallos, I. D., Ammerdorffer, A., Chinery, L., Coomarasamy, A., & Gülmezoglu, A. M. (2023). The compatibility of oxytocin and tranexamic acid injection products when mixed for co‐administration by infusion for the treatment of postpartum haemorrhage: An in vitro investigation. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.17398

Vancouver

Lambert P, Tomazzini A, Wright P, McEvoy C, Gallos ID, Ammerdorffer A, et al. The compatibility of oxytocin and tranexamic acid injection products when mixed for co‐administration by infusion for the treatment of postpartum haemorrhage: An in vitro investigation. BJOG: An International Journal of Obstetrics & Gynaecology. 2023. doi:10.1111/1471-0528.17398

BibTeX
@article{Lambert2023,
  author = {Lambert, Pete and Tomazzini, Alessandra and Wright, Philip and McEvoy, Claire and Gallos, Ioannis D and Ammerdorffer, Anne and Chinery, Lester and Coomarasamy, Arri and Gülmezoglu, Ahmet Metin},
  title = {The compatibility of oxytocin and tranexamic acid injection products when mixed for co‐administration by infusion for the treatment of postpartum haemorrhage: An in vitro investigation},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2023},
  doi = {10.1111/1471-0528.17398}
}
Kostenlos starten →